Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ross river virus vaccine + aluminum hydroxide
- Development stage
- Unknown
- Lead developer
- Queensland University of Technology
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A combination vaccine composed of the **Ross River virus vaccine**—typically utilizing a virus-like particle (VLP) platform—and **aluminum hydroxide** as an adjuvant. The Ross River virus vaccine is designed to induce an immune response against Ross River virus, which causes epidemic polyarthritis in humans. Aluminum hydroxide acts as an adjuvant by binding antigens, creating aggregates that enhance uptake by antigen-presenting cells, and stimulating the release of inflammatory cytokines such as IL-1β via NOD-like receptor NALP3 activation[1][2][4]. It primarily elicits a Th2-biased antibody response with limited stimulation of cytotoxic T-cell (Th1) immunity[1][2]. Adjuvanting with aluminum hydroxide is a standard formulation strategy for recombinant protein and VLP-based vaccines to increase immunogenicity and reduce antigen/dose requirements[1][4].
- Other names
- Ross River Virus VLP vaccine adjuvanted with aluminum hydroxide
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on ross river virus vaccine + aluminum hydroxide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ross river virus vaccine + aluminum hydroxide.